Quintiles has announced Jeffrey Spaeder as its chief medical and scientific officer.
A physician and cardiologist, Speader comes to the company from Takeda Pharmaceuticals International, where he served as executive director of global medical affairs.
He succeeds Oren Cohen, who has now moved to Quintiles’ Phase I clinical research business.
“Jeff will collaborate with Quintiles’ global operations and innovation colleagues to ensure the achievement of our strategic goals,” said Derek Winstanly, chief customer and governance officer.
North Carolina CRO Novella has named Mike Boyd as the new global head of clinical reporting.
He comes to the medical device company with 30 years of biostatistics and clinical trial experience, including in his last post at INC Research as senior director of global biostatistics.
Boyd will take the reigns for Novella’s four U.S. offices as well as operations in the United Kingdom and Russia, and will have executive oversight for all biostatistics and SAS news alert.
Wendel Barr has become the new chief executive at clinical research CRO Synteract.
Most recently at Covance, Barr has extensive experience in establishing strategy, expanding service and product lines.
Of his new role, he said: “It will be an exciting experience to work with this team to take this mid-sized company to the next level.”
Egenix has appointed Nils Bergenhem as president and chief scientific officer.
Bergenham brings 16 years experience in the field to the oncology drugs development company.
"Egenix approach to treating cancer has the potential to prevent uncontrolled cancerous cell growth, while not affecting normally growing cells," said Nils Bergenhem. "I am very excited to join Egenix, and help drive these programs forward to clinical application."
DBT Laboritories’ Lynn Allen has been promoted to director of business development for the Western U.S. Region & Europe.
Allen started off as a business development manager with the contract development and manufacturing organization (CDMO) back in 2005, and has since worked her way up the ranks to her new role.
Under Allen’s new leadership, DBT has restructured the Business Development team to address the rapidly expanding needs of its customers.
Paul Josephs, VP of sales and marketing, said: ““The sales team restructure helps ensure that we’re able to manage our growth and better serve our customers’ complex needs.”
AMRI has named Takeshi Yura as the new senior director of drug discovery services at its subsidiary AMRI Singapore Research Centre.
In his new expanded role Yura will take responsibility for the site’s overall management, which includes leadership of the AMRI Singapore Research Centre’s chemistry, biology and R&D operations.
He replaces Raymond Yeung, who has served as MD of the site since 2007.
Bruce Sargent, senior VP of drug discovery at AMRI said: “Since joining us earlier this year, we have been impressed with the extent of scientific and business leadership he has brought to AMRI and look forward to the additional contributions he will bring to the company in this new role.”
RecipharmCobra Biologics has appointed Julian Hanak as commercial director.
The international biopharmaceuticals manufacturers will call on the former Senior Vice President of Development at Renovo to build on the company’s growth in provision of manufacturing services for the biotech and biopharmaceutical industry.
Peter Coleman, CEO at RecipharmCobra Biologics, said: “I am delighted that Julian has decided to join RecipharmCobra Biologics as we look to strengthen our team’s depth of experience to expand our clinical production offering and to reach our goal as a leading commercial supplier for our customers. We all look forward to working with Julian to achieve these goals.”
PPD has announced it has appointed Edward Ian as VP of clinical development for Asia Pacific.
Before joining PPD, he held the positions of regional director of operations and senior director of clinical operations for Asia Pacific.
Ian will now provide strategic leadership and operational oversight for PPD's Phase II-IV business in the Singapore region.
PDI have named John Parsons as senior vice president and general manager of their new subsidiary Interpace BioPharma.
The company was formed to manage full product commercialization projects, and recently signed a two-and-a-half-year agreement for the sales and marketing of a treatment for knee pain.
Parsons takes the reins after a stint as president and chief commercial officer of the US division of biopharmaceutical company TopoTarget A/S.
Mark Sneff is the new VP of human resources at Premier Research Group.
With more than 25 years experience in human resources and operations within international pharmaceutical development, Sneff’s latest post was as senior VP in human resources for Critical Homecare Solutions.
He also served as VP of global human resources for Covance clinical development division.
If you have recently joined a new company, changed roles, or have someone new to your company, then please send us your press release along with a photograph for our weekly people column. The address to send it to is firstname.lastname@example.org.